Newsfeeds - Spark Newswire

1 minute read

Goldman Sachs Downgrades Altimmune to Neutral, Lowers Price Target to $6

Today, 6:54 AM

Goldman Sachs analyst Corinne Jenkins downgrades Altimmune (NASDAQ:ALT) from Buy to Neutral and lowers the price target from $20 to $6.

ALT

1 minute read

Analyst Ratings

Analyst Ratings for Altimmune

By Benzinga Insights

Today, 6:54 AM

Altimmune (NASDAQ:ALT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

ALT

4 minute read

Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 6:54 AM

Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.

ADPT

1 minute read

Altimmune Touts Encouraging Data From Fatty Liver Disease Study

By Vandana Singh

Today, 6:54 AM

Altimmune Inc (NASDAQ:ALT) announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease…

ALT

3 minute read

Altimmune Announced Trial Met Its Primary Endpoint in All Pemvidutide Treatment Groups

By Charles Gross

Today, 6:54 AM

- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with NAFLD.

ALT

5 minute read

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 6:54 AM

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

ACLX

15 minute read